Pharma Journalist -

Ferrer has announced that its investigational therapy FNP-223, developed to treat progressive supranuclear palsy (PSP), has received Fast Track designation from the U.S. Food and Drug…
Read More...

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of…
Read More...

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, launches from stealth having raised a total of $140 million (£107…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational drug DYNE-101 for the treatment of…
Read More...

BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that the U.S. Food and Drug Administration (FDA) has…
Read More...

Eli Lilly and Company and Verve Therapeutics, Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for…
Read More...

Lisata Therapeutics, Inc. and GATC Health Corp. announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process. This…
Read More...

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy…
Read More...

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), announced an international collaboration with…
Read More...

The 2025 summit offers an in-depth look at the most innovative technologies and scientific strategies shaping the future of microbiome-based therapies. This includes advancements in…
Read More...